KODIAK SCIENCES INC (KOD) Stock Price, Quote, News and Overview
NASDAQ:KOD - Nasdaq - US50015M1099 - Common Stock - Currency: USD
KOD Quote, Performance and Key Statistics
4.45
-0.29 (-6.12%)
The current stock price of KOD is 4.45 USD. In the past month the price decreased by -46.45%. In the past year, price decreased by -16.04%.
KOD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About KOD
Company Profile
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 108 full-time employees. The company went IPO on 2018-10-04. The firm has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. The company is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Company Info
KODIAK SCIENCES INC
1200 Page Mill Rd
Palo Alto CALIFORNIA 94304 US
CEO: Victor Perlroth
Employees: 108
Company Website: https://kodiak.com/
Investor Relations: https://ir.kodiak.com/
Phone: 16502810850
KODIAK SCIENCES INC / KOD FAQ
What is the stock price of KODIAK SCIENCES INC today?
The current stock price of KOD is 4.45 USD. The price decreased by -6.12% in the last trading session.
What is the ticker symbol for KODIAK SCIENCES INC stock?
The exchange symbol of KODIAK SCIENCES INC is KOD and it is listed on the Nasdaq exchange.
On which exchange is KOD stock listed?
KOD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KODIAK SCIENCES INC stock?
14 analysts have analysed KOD and the average price target is 7.14 USD. This implies a price increase of 60.45% is expected in the next year compared to the current price of 4.45. Check the KODIAK SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KODIAK SCIENCES INC worth?
KODIAK SCIENCES INC (KOD) has a market capitalization of 234.16M USD. This makes KOD a Micro Cap stock.
How many employees does KODIAK SCIENCES INC have?
KODIAK SCIENCES INC (KOD) currently has 108 employees.
What are the support and resistance levels for KODIAK SCIENCES INC (KOD) stock?
KODIAK SCIENCES INC (KOD) has a support level at 2.78. Check the full technical report for a detailed analysis of KOD support and resistance levels.
Should I buy KODIAK SCIENCES INC (KOD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KOD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KOD, evaluating the profitability, health, valuation and growth aspects
- KODIAK SCIENCES INC (KOD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KODIAK SCIENCES INC (KOD) Sales and EPS estimates to see what analysts future expectations are.
- KODIAK SCIENCES INC (KOD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KODIAK SCIENCES INC (KOD) Insider and Institutional Ownership to learn about the owners and their transactions.
- KODIAK SCIENCES INC (KOD) Stock Chart to make your own analysis
- KODIAK SCIENCES INC (KOD) Latest news and press-releases to stay up to date.
Does KODIAK SCIENCES INC (KOD) stock pay dividends?
KOD does not pay a dividend.
When does KODIAK SCIENCES INC (KOD) report earnings?
KODIAK SCIENCES INC (KOD) will report earnings on 2025-03-26, after the market close.
What is the Price/Earnings (PE) ratio of KODIAK SCIENCES INC (KOD)?
KODIAK SCIENCES INC (KOD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.65).
What is the Short Interest ratio of KODIAK SCIENCES INC (KOD) stock?
The outstanding short interest for KODIAK SCIENCES INC (KOD) is 4.1% of its float. Check the ownership tab for more information on the KOD short interest.
KOD Technical Analysis
KOD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KOD. While KOD seems to be doing ok healthwise, there are quite some concerns on its profitability.
KOD Financial Highlights
Over the last trailing twelve months KOD reported a non-GAAP Earnings per Share(EPS) of -3.65. The EPS increased by 29.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.42% | ||
| ROE | -103.37% | ||
| Debt/Equity | 0 |
KOD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 51% to KOD. The Buy consensus is the average rating of analysts ratings from 14 analysts.